The consensus marks a sequential improvement from the third quarter, when Amneal earned $0.17 per share on revenue of $785 million. Investors will scrutinize whether the Bridgewater, N.J.-based ...
The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a ...
3don MSN
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or ...
Novo Nordisk A/S NVO announced plans on Tuesday to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027. The price reduction will affect the obesity injection Wegovy, its ...
Novo Nordisk announced plans to drastically reduce the list price of its versions, Wegovy, Ozempic and Rybelsus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results